Genetically Engineered Insulin Analogs: Diabetes in the New Millenium
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Tight glucose control is essential to minimize complications in diabetic patients. However, the pharmacokinetic characteristics of the currently available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. Until recently, improvements in insulin formulations were seriously limited as advances were only achieved in insulin purity, species, and characteristics of the retarding agent. The availability of molecular genetic techniques opened new windows to create insulin analogs by changing the structure of the native protein and to improve the therapeutic properties. The first clinically available insulin analog, Lispro, confirmed the hopes by showing that improved glycemic control can be achieved without an increase in hypoglycemic events. This requires, however, optimal basal insulin replacement, either by multiple daily injections of neutral protein Hagedorn (NPH) insulin or by insulin pump. Evidence suggests that short-acting insulin analogs would be better matched by a true basal insulin than by the erratically absorbed and rather short-acting NPH insulin. Therefore, future availability of long-acting analogs raises the hope to realize the true potential benefits of the currently available short-acting analog, Lispro, and of those still awaiting approval. The introduction of new short-acting and the first truly long-acting analogs, the development of analogs with increased stability, less variability and perhaps selective action will help to develop more individualized treatment strategies targeted to specific patient characteristics and to achieve further improvements in glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Brunelle, R. L., Llewelyn, J., Anderson, J. H., Gale, E. A. M., & Koivisto, V. A. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1726 · Cited by 216
Cited by
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Cytokines and the central nervous system
Szelényi, J. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00428-2 · Cited by 358
Type 1 diabetes: recent developments
Devendra, D., Liu, E., & Eisenbarth, G. S. (2004) · BMJ · doi:10.1136/bmj.328.7442.750 · Cited by 353
Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle, M. E., & Egan, J. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.7 · Cited by 256
Hofmann, T., Horstmann, G., & Stammberger, I. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096315 · Cited by 77
Metadata
- Authors
- Vajo, Z., & Duckworth, W. C.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2000-03
- Volume
- 52
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2163117054
- Cited by
- 83
- References
- 2
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically Engineered Insulin Analogs: Diabetes in the New Millenium. https://app.cochat.ai/papers/10.1016/s0031-6997(24)01433-9
- The paper
- Vajo, Z., & Duckworth, W. C. (2000). Genetically Engineered Insulin Analogs: Diabetes in the New Millenium. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(24)01433-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.